Ca2+-induced oxidative stress in brain mitochondria treated with the respiratory chain inhibitor rotenone  by Sousa, Solange C. et al.
Ca2þ-induced oxidative stress in brain mitochondria treated with
the respiratory chain inhibitor rotenone
Solange C. Sousa, Evelise N. Maciel, Anibal E. Vercesi, Roger F. Castilho
Departamento de Patologia Cl|¤nica, Faculdade de Cie“ncias Me¤dicas, Universidade Estadual de Campinas, Campinas, SP 13083-970, Brazil
Received 28 February 2003; revised 4 April 2003; accepted 14 April 2003
First published online 29 April 2003
Edited by Vladimir Skulachev
Abstract In this study we show that micromolar Ca2+ concen-
trations (s 10 WM) strongly stimulate the release of reactive
oxygen species (ROS) in rotenone-treated isolated rat forebrain
mitochondria. Ca2+-stimulated mitochondrial ROS release was
associated with membrane lipid peroxidation and was directly
correlated with the degree of complex I inhibition by rotenone.
On the other hand, Ca2+ did not increase mitochondrial ROS
release in the presence of the complex I inhibitor 1-methyl-4-
phenylpyridinium. Cyclosporin A had no e¡ect on Ca2+-stimu-
lated mitochondrial ROS release in the presence of rotenone,
indicating that mitochondrial permeability transition is not in-
volved in this process. We hypothesized that Ca2+-induced mi-
tochondrial oxidative stress associated with partial inhibition of
complex I may be an important factor in neuronal cell death
observed in the neurodegenerative disorder Parkinson’s disease.
. 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Post mortem studies have shown evidence that oxidative
stress and mitochondrial dysfunction are involved in the
pathogenesis of idiopathic Parkinson’s disease (PD). Indica-
tions of oxidative stress include depletion of reduced gluta-
thione, iron accumulation and the presence of lipid, protein
and DNA oxidation products [1^3]. Mitochondrial dysfunc-
tion is mainly suggested by a partial inhibition (20^40%) of
respiratory chain complex I activity [4,5], present also in pe-
ripheral tissues [6,7].
Recently Betarbet and collaborators [8] showed that
chronic treatment of rats with the mitochondrial complex I
inhibitor rotenone results in selective nigrostriatal dopaminer-
gic degeneration, including formation of Lewy bodies and cell
loss. However, the concentration of rotenone found in the rat
brains was insu⁄cient to substantially inhibit mitochondrial
respiration [8], indicating that a bioenergetic defect with ATP
depletion could not explain the reported neurodegeneration.
Under these conditions, an increased mitochondrial produc-
tion of reactive oxygen species (ROS) secondary to partial
inhibition of complex I could contribute to rotenone-induced
nigrostriatal dopaminergic degeneration [9,10]. This experi-
mental model for PD resembles the classical selective degen-
eration of dopaminergic neurons obtained by systemical treat-
ment of primates and rodents with N-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) (for a review see [11]). MPTP
toxicity for dopaminergic neurons occurs when it is converted
to the active neurotoxin, 1-methyl-4-phenylpyridiniun ion
(MPPþ), an inhibitor of mitochondrial respiratory chain com-
plex I [11,12].
Glutamate receptor-mediated neuronal cell death ^ i.e. ex-
citotoxicity ^ has been hypothesized to be involved in the
pathogenesis of PD [13,14]. In excitotoxicity, Ca2þ in£ux to
the cytosol is correlated with cellular toxicity [15,16]. In this
paper, we study the e¡ect of Ca2þ on rotenone-treated iso-
lated rat forebrain mitochondria. The results indicate that
micromolar Ca2þ concentrations induce mitochondrial oxida-
tive stress in the presence of rotenone. The possible implica-
tions of this observation for the progressive neurodegenera-
tion observed in PD are discussed.
2. Materials and methods
2.1. Mitochondrial isolation
Mitochondria were isolated by conventional di¡erential centrifuga-
tion from forebrains of adult female Wistar strain rats as described by
Rosenthal et al. [17]. Digitonin was used to disrupt synaptosomal
membranes and release any mitochondria trapped within. The ¢nal
pellet was resuspended in medium containing 225 mM mannitol, 75
mM sucrose, 5 mM Kþ-HEPES pH 7.2 and 1 mg/ml bovine serum
albumin, at an approximate protein concentration of 30^40 mg/ml.
Rat liver and gastrocnemius muscle mitochondria were isolated by the
same procedure described above for forebrain mitochondria, includ-
ing the addition of digitonin to the second pellet.
2.2. Standard incubation procedure
The experiments were carried out at 28‡C, with continuous mag-
netic stirring, in a standard reaction medium containing 100 mM
sucrose, 65 mM KCl, 10 mM Kþ-HEPES bu¡er (pH 7.2), 50 WM
EGTA, 1 mM Pi, 2 mM Mg2þ, 5 mM malate, 10 mM pyruvate,
200 WM ATP and 1 Wg/ml oligomycin. Other additions are indicated
in the ¢gure legends. The results shown are representative of a series
of at least four experiments, using di¡erent mitochondrial prepara-
tions. The results were reproduced within 10% of variation.
2.3. Oxygen uptake measurements
Oxygen consumption was measured using a Clark-type electrode
(Yellow Springs Instruments, OH, USA) in 1.3 ml of standard reac-
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tion medium, in a sealed glass cuvette equipped with a magnetic
stirrer.
2.4. Estimation of mitochondrial ROS release
Mitochondrial release of ROS (H2O2) was determined spectro-
£uorometrically, using the membrane-permeable £uorescent dye di-
chlorodihydro£uorescein diacetate (H2-DCFDA; 1 WM) [18,19]. Fluo-
rescence was determined at 488 nm for excitation and 525 nm for
emission. Calibration was performed by adding known concentrations
of dichloro£uorescein (DCF), the product of H2-DCF oxidation. Al-
ternatively ROS were measured using either 200 nM MitoTracker0
Red CM-H2XRos, at 579 nm for excitation and 599 nm for emission;
1 WM scopoletin plus 1 WM horseradish peroxidase, at 365 nm for
excitation and 450 nm for emission; or 50 WM Amplex Red plus 0.025
WM horseradish peroxidase [20], at 563 nm for excitation and 587 nm
for emission. The rate of mitochondrial H2O2 release detected under
control conditions when using the horseradish peroxidase substrates
scopoletin and Amplex Red was 42Q6 and 245Q 26 pmol H2O2/min/
mg, respectively.
2.5. Determination of thiobarbituric acid reactive substances (TBARS)
TBARS production in mitochondria was measured as described by
Maciel et al. [19].
2.6. Materials
Most chemicals, including ATP, antimycin A, cyclosporin A, dig-
itonin, HEPES, malic acid, MPPþ, myxothiazol, pyruvic acid, rote-
none (R-8875, minimum 95%), scopoletin and thiobarbituric acid
were obtained from Sigma Chemical Company (St. Louis, MO,
USA). Amplex Red, H2-DCFDA and MitoTracker Red CM-H2XRos
were purchased from Molecular Probes (Eugene, OR, USA). Rote-
none was prepared at a stock concentration of 1 mM in 100% ethanol.
3. Results
Mitochondrial ROS release was measured using the mem-
brane-permeable probe H2-DCFDA, which is oxidized mainly
by H2O2 and peroxynitrite [18,21] generating highly £uores-
cent DCF. The results in Fig. 1A show that the addition of
Ca2þ to isolated rat brain mitochondria treated with rotenone
strongly stimulates ROS detection (line d). A fast increase in
the rate of DCF production was observed 3^5 min after Ca2þ
addition. Rotenone alone did not increase the rate of DCF
production (line b) while only Ca2þ addition in the absence of
rotenone slightly stimulates ROS detection (line c). Similar
results were obtained using the mitochondrial respiratory sub-
strates glutamate/malate instead of pyruvate/malate (results
not shown). The increased release of ROS promoted by rote-
none and Ca2þ was completely blocked by Ca2þ removal by
EGTA (Fig. 1B, line b) or by the H2O2-removing system
ebselen plus glutathione (line c). In Fig. 1C, we tested the
e¡ect of Ca2þ on brain mitochondria treated with the complex
I inhibitor MPPþ, a classical dopaminergic neurotoxin [11].
Interestingly, MPPþ alone increased the rate of DCF produc-
tion (line b) without any further stimulatory e¡ect of Ca2þ
addition (line c). The results of Fig. 1D show the e¡ect of
di¡erent concentrations of Ca2þ (rotenone at 100 nM) and
di¡erent concentrations of rotenone (free Ca2þ at 50 WM)
on H2-DCF oxidation.
Since a partial inhibition (20^40%) of mitochondrial com-
plex I activity has been detected in PD patients [4,5,7], we
tested if a partial inhibition of mitochondrial respiration by
rotenone would increase the rate of ROS release in the pres-
ence of Ca2þ. The results of Fig. 2A show that, under our
experimental conditions, 5 nM rotenone results in 30^40%
inhibition of uncoupled mitochondrial respiration supported
by NADH-linked substrates. Using this rotenone concentra-
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Fig. 1. Ca2þ-induced increase in ROS release in isolated brain mitochondria treated with rotenone: e¡ect of rotenone and Ca2þ concentrations.
Isolated forebrain mitochondria (0.5 mg/ml) were added to standard reaction medium containing 1 WM H2-DCFDA. In A, 50 nM rotenone
(lines b and d) and 120 WM Ca2þ (lines c and d) were added to the experiments where indicated by the arrows. In B, 50 nM rotenone (lines b,
c and d), 120 WM Ca2þ (lines b, c and d), 10 WM ebselen plus 200 WM glutathione (line b) and 500 WM EGTA (line c) were added to the ex-
periments where indicated by the arrows. In C, 1 mM MPPþ (lines b and c) and 120 WM Ca2þ (line c) were added where indicated by the ar-
rows. Panel D shows the e¡ect of di¡erent concentrations of rotenone (free Ca2þ at 50 WM) (R) and di¡erent concentrations of Ca2þ (rotenone
at 100 nM) (b) on H2-DCF oxidation. Lines a represent control experiments without the addition of rotenone, MPPþ and Ca2þ.
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tion, in the presence of Ca2þ, we observed a nearly 200%
increase in the rate of the detection of mitochondrially gen-
erated ROS (Fig. 2B).
The e¡ect of cyclosporin A, an inhibitor of mitochondrial
permeability transition (MPT; for a review see [22]), was
tested on mitochondrial ROS release (Fig. 3). Cyclosporin A
had no inhibitory e¡ect on rotenone plus Ca2þ-induced in-
creased release of ROS (line c), indicating that MPT is not
involved in this process. In addition, the results of Fig. 3 show
that the protonophore carbonyl cyanide-p-tri£uoromethoxy-
phenyl hydrazone (FCCP; line d) does not inhibit Ca2þ plus
rotenone-induced increased release of mitochondrial ROS,
and the mitochondrial respiratory chain inhibitors antimycin
A (line e) and myxothiazol (line f) do not substitute rotenone
in stimulating mitochondrial ROS release in the presence of
Ca2þ. Interestingly Ca2þ slightly inhibited antimycin A-stimu-
lated mitochondrial ROS release (result not shown).
In Fig. 4, mitochondrial ROS release was measured using
the membrane-permeable £uorescent dye Mito-Tracker Red
CM-H2XRos (Fig. 4A), or the £uorescent peroxidase sub-
strates scopoletin (Fig. 4B) and Amplex Red (Fig. 4C), in
order to guarantee that the results obtained with H2-DCFDA
were accurate. The presence of rotenone plus Ca2þ strongly
stimulated ROS detection using any of these methods, while
rotenone in the absence of Ca2þ resulted in a smaller stimu-
latory e¡ect on ROS detection that was more pronounced
when using Amplex Red. Ca2þ alone did not increase the
rate of ROS detection. The results obtained with Mito-Track-
er Red and Amplex Red (Fig. 4A,C) are in accordance with
recent reports showing a stimulatory e¡ect of rotenone on
mitochondrial ROS release [10,23].
Mitochondrial lipid peroxidation was quanti¢ed in order to
study a possible correlation between Ca2þ plus rotenone-in-
duced increased release of ROS and membrane damage (Fig.
5). Incubation of brain mitochondria in the presence of Ca2þ
plus rotenone increased the basal content of TBARS three- to
four-fold, while either Ca2þ or rotenone had no signi¢cant
e¡ect on the basal content of TBARS.
4. Discussion
In the present work, we report that micromolar Ca2þ con-
centrations in the presence of rotenone strongly increase the
detection of ROS production in isolated rat forebrain mito-
chondria. This Ca2þ e¡ect was dose dependent, while the ef-
fect of rotenone was correlated with the degree of inhibition
of uncoupled (respiratory state 3) mitochondrial respiration
(Figs. 1 and 2). Mitochondrial oxidative damage was evi-
denced by increased membrane lipid peroxidation in the pres-
ence of Ca2þ plus rotenone (Fig. 5). The e¡ect of Ca2þ and
rotenone on mitochondrial ROS release was only observed for
isolated forebrain mitochondria, and not for organelles iso-
lated from two other tissues, liver and muscle (results not
shown). Although we have no plausible explanation for the
selective e¡ect of Ca2þ plus rotenone to brain mitochondria,
this e¡ect correlates with the selective pathology of PD to the
nervous system [1,24].
Interestingly, Ca2þ did not stimulate MPPþ-induced in-
crease in mitochondrial ROS release (Fig. 1), and Ca2þ did
not stimulate ROS release in brain mitochondria treated with
antimycin A or myxothiazol, inhibitors of respiratory chain
complex III (Fig. 3). These results suggest that the e¡ect of
Ca2þ on increasing ROS release under a condition of partial
inhibition of the mitochondrial respiratory chain may be spe-
ci¢c for the rotenone-sensitive site of complex I. The ability of
Ca2þ to stimulate mitochondrial ROS generation may be at-
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Fig. 2. A partial respiratory chain inhibition by rotenone results in mitochondrial oxidative stress in the presence of Ca2þ. In A, forebrain mi-
tochondria (0.5 mg/ml) were incubated in standard reaction medium, without ATP and oligomycin, in the absence (S) or presence or 1 mM
ADP (b). In B, forebrain mitochondria (0.5 mg/ml) were incubated in standard reaction medium, 5 nM rotenone (line c) and 120 WM Ca2þ
(lines b and c) were added where indicated by the arrows. Line a represents a control experiment without the addition of rotenone and Ca2þ.
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Fig. 3. E¡ect of cyclosporin A, FCCP and respiratory chain inhibi-
tors on mitochondrial ROS release in the presence of Ca2þ. Fore-
brain mitochondria (0.5 mg/ml) were added to standard reaction
medium containing 1 WM cyclosporin A (line c), 1 WM FCCP (line
d), or no other additions (lines a, b, e and f). Mitochondrial respira-
tory chain inhibitors (R.C.I.), 50 nM rotenone (lines b^d), 0.5 WM
antimycin A (line e) or 0.5 WM myxothiazol (line f) were added
where indicated by the arrow. Ca2þ was added to the experiments
represented by lines b^f where indicated by the arrow. Line a repre-
sents a control experiment without the addition of respiratory chain
inhibitors and Ca2þ.
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tributed to alterations promoted by this cation on the mito-
chondrial membrane structure, possibly through binding to
cardiolipins of the inner mitochondrial membrane [25]. These
alterations are characterized by an increased lipid packing and
lipid domain formation that may contribute toward electron
leakage at the respiratory chain complex I [25].
Under our experimental conditions, Ca2þ-induced oxidative
stress in rotenone-treated brain mitochondria does not seem
to depend on mitochondrial Ca2þ accumulation. The Ca2þ
e¡ect was observed even in the presence of high rotenone
concentrations and FCCP (Fig. 3), situations in which mito-
chondrial Ca2þ uptake is limited due to dissipation of the
transmembrane electrical potential (v8). These results indi-
cate that Ca2þ could be acting at an external site of the inner
mitochondrial membrane facing the intermembrane space to
stimulate ROS release in the presence of rotenone. High Ca2þ
concentrations could also induce MPT, a phenomenon char-
acterized by a non-speci¢c inner membrane permeabilization
(for reviews see [22,26]) that results in increased detection of
mitochondrial ROS production [19]. In our experiments, we
had no indications of the participation of permeability tran-
sition (Fig. 3), probably because the experiments were con-
ducted in the presence of ATP and Mg2þ, e¡ective inhibitors
of this phenomenon in isolated brain mitochondria [27]. Re-
cently, Starkov and collaborators [28] reported that Ca2þ ap-
proximately doubles brain mitochondrial ROS release in the
presence of rotenone. However, di¡erent from the present
study, the results reported by Starkov and collaborators [28]
were obtained using succinate as respiratory substrate, a sit-
uation in which mitochondrial Ca2þ uptake and retention are
maintained even in the presence of high concentrations of
rotenone. Moreover, using succinate as substrate rotenone
decreases by 70^80% mitochondrial ROS release and the pres-
ence of Ca2þ seems only to decrease this inhibitory e¡ect of
rotenone. In fact, the rate of H2O2 detection in the presence
of rotenone and Ca2þ was lower than in their absence [28].
Recently, Barrientos and Moraes [9] showed that a partial
inhibition of mitochondrial complex I activity is not enough
to explain neuronal cell death primarily by energy depriva-
tion. Moreover, partial inhibition of complex I, obtained ei-
ther by genetic modi¢cation of cell lines or rotenone treat-
ment, promotes cell death in a manner quantitatively
associated with increased free radical production, and not
with a decrease in respiratory chain function [9]. This is in
accordance with several reports showing an increased produc-
tion of mitochondrial ROS after brain mitochondrial complex
I inhibition [9,10,23,29]. A partial inhibition of respiratory
chain complex I may also cause a subliminal energy depriva-
tion that could increase the susceptibility of nigral neurons to
glutamate receptor-mediated cell death, i.e. excitotoxicity
[15,16].
In conclusion, our results show that micromolar Ca2þ con-
centrations induce oxidative stress in isolated brain mitochon-
dria when complex I is partially inhibited by rotenone. A low
grade excitotoxicity, promoted predominantly by hyperstimu-
lation of N-methyl-D-aspartate receptors, which mediated Naþ
and Ca2þ in£ux to the cytosol, has been proposed to play an
important role in the neuropathology of PD [13,14]. Under
these conditions, Ca2þ-stimulated mitochondrial ROS release
may participate as an important link between the partial mi-
tochondrial complex I inhibition and oxidative damage ob-
served in PD.
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Fig. 4. Rotenone plus Ca2þ-induced increase in detection of ROS in isolated brain mitochondria: measurement of ROS using di¡erent methods.
Forebrain mitochondria (0.5 mg/ml) were incubated in standard reaction medium containing 200 nM MitoTracker Red CM-H2XRos (A), 1 WM
scopoletin plus 1 WM horseradish peroxidase (B) or 50 WM Amplex Red plus 0.025 WM horseradish peroxidase (C). Rotenone (50 nM) and/or
120 WM Ca2þ were added to the experiments as indicated in the ¢gure. Values represent averages of three to four experiments ( QS.E.M.), using
di¡erent mitochondrial preparations. *P6 0.01, post hoc Bonferroni/Dunn’s test compared with control. #P6 0.01, post hoc Bonferroni/Dunn’s
test compared with rotenone.
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Fig. 5. Rotenone plus Ca2þ-induced TBARS formation. Forebrain
mitochondria (0.5 mg/ml) were incubated in standard reaction me-
dium for 30 min in the presence of 50 nM rotenone and/or 120 WM
Ca2þ as indicated in the ¢gure. Fe2þ (20 WM) plus 2 mM citrate
were used to induce lipid peroxidation independent of mitochondri-
ally generated ROS [19]. Values represent averages of ¢ve experi-
ments ( Q S.E.M.), using di¡erent mitochondrial preparations.
*P6 0.01, post hoc Bonferroni/Dunn’s test compared with control.
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